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Fatal Infusion Reaction to Cetuximab: The
Need for Predictive Risk Factors and Safer
Patient Selection
Case Report
A 63-year-oldmanwith a history ofmetastatic colon cancer and
a wild-type KRAS genotype visited our institution as an outpatient.
The patient had previously received oxaliplatin- and irinotecan-based
chemotherapy and pulmonary resection. At our institution, he re-
ceived the first course of a combined irinotecan and cetuximab treat-
ment. He was in excellent health with no significant complaints or
tumor-relatedsymptoms.Hismedicalhistorywasuninformative, and
he reported no comorbidity and no known allergies.
A few minutes before the infusion, the patient had normal vital
signs (including blood pressure and heart rate) and a normal blood
count. The protocol at our institution required premedication with
chlorpheniramine (10mg intravenously [IV]), dexamethasone (8mg
IV), andatropine (0.25mgsubcutaneously)before the administration
ofcetuximab(400mg/m2 IVinfusiondeliveredover120minutes)and
irinotecan (180mg/m2 IV infusion delivered over 90minutes). A few
minutes after this treatment finished, the patient began to exhibit
sialorrhea, sweating, anddiarrhea,whichwas indicative of irinotecan-
induced cholinergic syndrome. However, despite the administration
of atropine (0.5 mg subcutaneously), the symptoms rapidly deterio-
rated. He experienced dyspnea, expectoration of a white, frothy mu-
cus, and initial decrease in the level of consciousness. The patient’s
oxygen saturation fell to 70% in ambient air, and bilateral rales and
ronchi were detected on chest auscultation. The patient was admitted
to the intensive care unit. He underwent intubation and mechanical
ventilation with supplemental oxygen, but he rapidly developed
marked respiratory distress with severe acidosis.
A first chest x-ray performed two hours after the drug infusion
showed bilateral pulmonary infiltrates and initial lower pulmonary
lobes hypoventilation. These findings were particularly noted in the
lower pulmonary lobes (Fig 1). A subsequent chest x-ray performed
three hours later showed a significant worsening of pulmonary hy-
poventilation and the likely appearance of right pleural effusion (Fig
2). No left ventricular dysfunction was demonstrated on trans-
thoracic echocardiography. Ten hours after the onset of symptoms
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and after two successive cardiac arrests, the patient died. The autopsy
revealed diffuse, acute, alveolar hematic congestion without any ac-
companyingacutecardiaceventsorother causative conditions (Fig3).
Discussion
Cetuximab is a chimeric anti–epidermal growth factor receptor
monoclonal antibody created by combining the antigen-binding re-
gions of the mouse antibody with the constant region of the human
immunoglobulin.1 Severe infusion reactions have been estimated to
occur in 1% to 8%of patients.2-4 Themost common signs and symp-
toms are chills, fever, urticaria, hypotension, bronchospasm, and
other respiratory conditions. Formost patients, the reaction is revers-
ible with the use of IV fluids, steroids, antihistamines, bronchodila-
tors, and epinephrine. Most patients who experience a reaction,
particularly when the symptoms are mild to moderate, can safely
continue the treatment with proper medication and close monitor-
ing.5,6 However, infusion reactions can occasionally cause death1
( 0.1% of cases).
The pathogenicmechanisms underlying the development of this
phenomenonremain tobeelucidated. Its earlyoccurrence (during the
first infusion in 90%of cases) supports the role of an immunoglob-
ulin E–independentmechanism.5 Atopic history and previous hyper-
sensitivity have been suggested to increase the risk of developing an
infusion reaction. However, no definitive data exist about the exact
role of these factors.4 Despite the generally favorable outcome of
cetuximab-associated reactions, the potential occurrence of fatal
events, as described in this report, warrants the search for reliable risk
factors that can facilitate the safe selection of patients as candidates for
cetuximab-based treatment.
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